Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials.
Spasticity is characterized by increased muscle stiffness and spasms, which can be uncomfortable and hinder movement.
Jazz Pharmaceuticals' Study
The study, funded by GW Pharmaceuticals (now part of Jazz Pharmaceuticals) (NASDAQ: JAZZ), the developer of Nabiximols, showed that oral spray therapy led to a reduction in spasticity symptoms and daily muscle spasm counts among participants.
Nabiximols, marketed as Sativex, is approved for treating MS-related spasticity in …